Researcher
Sandrine Aspeslagh
- Keywords:Medicine
Affiliations
- Internal medicine (Department)
Member
From1 May 2023 → Today - Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Medical Oncology (Department)
Member
From1 Feb 2019 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → 20 Oct 2022 - Clinical sciences (Department)
Member
From15 Nov 2020 → 14 Nov 2022
Projects
1 - 1 of 1
- FORX - FOod interventions to Reduce immunotherapy toXicityFrom1 Nov 2023 → TodayFunding: FWO fellowships
Publications
11 - 20 of 71
- Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma(2022)
Authors: Jeroen De Filette, Stéphanie André, Lynn De Mey, Sandrine Aspeslagh, Rafik Karmali, Bart J Van der Auwera, Bert Bravenboer
Pages: 1-5 - Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients(2022)
Authors: T Van Meerhaeghe, J.f. Baurain, Oliver Bechter, C Orte Cano, V. Del Marmol, Arnaud Devresse, P Doubel, M. Hanssens, R Hellemans, D. Lienard, et al.
- Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients(2022)
Authors: Justine Lauwyck, Max Schreuer, Laurent Meric de Bellefon, Joanna Van Erps, Bart Neyns, Sandrine Aspeslagh
Pages: 200-204 - Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade(2022)
Authors: Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, et al.
- COVID-19 and Cushing's disease in a patient with ACTH-secreting pituitary carcinoma(2022)
Authors: Jeroen M.K. de Filette, Bastiaan Sol, Gil Awada, Corina Andreescu, David Unuane, Sandrine Aspeslagh, Jan Poelaert, Bert Bravenboer
Pages: 1-4 - Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab(2022)
Authors: C Orte Cano, T Van Meerhaeghe, Julio Tannous, D. Lienard, Dirk Van Gestel, Nicolas Cuylits, S. Luce, S Carlot, A. Le Moine, Sandrine Aspeslagh, et al.
Pages: 53-58 - Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors(2021)
Authors: André Manuel Da Silva Lopes, Sara Colomer-Lahiguera, Nuria Mederos Alfonso, Veronica Aedo-Lopez, Gilliosa Spurrier-Bernard, Lærke Kjær Tolstrup, Helle Pappot, Sandrine Aspeslagh, Anne Rogiers, Bart Neyns, et al.
Pages: 225-237 - C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting(2021)
Authors: Justine Lauwyck, Aline Beckwée, Arno Santens, Julia Katharina Schwarze, Gil Awada, Valerie Vandersleyen, Sandrine Aspeslagh, Bart Neyns
Pages: 371-377 - A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder(2021)
Authors: Xiaoxiao Wang, Mariano Suppa, Pascal Bruderer, Nicolas Sirtaine, Sandrine Aspeslagh, Joseph Kerger
Pages: 861-867 - Delayed immune-related adverse events with an PD-1-based immunotherapy in melanoma(2021)
Authors: C. N. Owen, Xiaoyu Bai, T. Quah, S. N. Gosling,, Clara Allayous, S. Callaghan, C. Martinez-Vila, Graham R Wallace, Prachi Bhave, I. L. M. Reijers, et al.
Pages: 917-925